Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface

[1]  W. Wurst,et al.  Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity , 2007, Nature Medicine.

[2]  M. Siddiqui,et al.  Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. , 2006, Vascular pharmacology.

[3]  M. Eren,et al.  Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. , 2006, American journal of physiology. Heart and circulatory physiology.

[4]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[5]  U. Rapp,et al.  Raf kinases: Oncogenesis and drug discovery , 2006, International journal of cancer.

[6]  M. Nishida,et al.  TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy , 2006, The EMBO journal.

[7]  E. Olson,et al.  Canonical Transient Receptor Potential Channels Promote Cardiomyocyte Hypertrophy through Activation of Calcineurin Signaling* , 2006, Journal of Biological Chemistry.

[8]  L. Leinwand,et al.  Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A. , 2006, American journal of physiology. Cell physiology.

[9]  D. Steven,et al.  Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. , 2006, Free radical biology & medicine.

[10]  J. Melendez,et al.  Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation. , 2006, Journal of molecular and cellular cardiology.

[11]  L. Kirshenbaum,et al.  RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes. , 2006, Cellular signalling.

[12]  I. Shiojima,et al.  Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. , 2006, Physiological genomics.

[13]  D. Castrillon,et al.  Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling , 2006, Circulation.

[14]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[15]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[16]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[17]  Mark A Sussman,et al.  Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy , 2006, Proceedings of the National Academy of Sciences.

[18]  Timothy E. Hewett,et al.  Pharmacological- and Gene Therapy–Based Inhibition of Protein Kinase Cα/β Enhances Cardiac Contractility and Attenuates Heart Failure , 2006 .

[19]  Ji Myoung Kim,et al.  PICOT Inhibits Cardiac Hypertrophy and Enhances Ventricular Function and Cardiomyocyte Contractility , 2006, Circulation research.

[20]  H. Nakayama,et al.  Calcineurin‐dependent cardiomyopathy is activated by TRPC in the adult mouse heart , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  H. Schulman,et al.  Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease , 2006, Nature Clinical Practice Cardiovascular Medicine.

[22]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[23]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[24]  E. Olson,et al.  CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. , 2006, The Journal of clinical investigation.

[25]  T. Kálai,et al.  PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. , 2006, Journal of molecular and cellular cardiology.

[26]  E. Olson,et al.  Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.

[27]  Rick B. Vega,et al.  Regulation of Cardiac Stress Signaling by Protein Kinase D1 , 2006, Molecular and Cellular Biology.

[28]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[29]  Robert D. Gerard,et al.  The Transcriptional Coactivator CAMTA2 Stimulates Cardiac Growth by Opposing Class II Histone Deacetylases , 2006, Cell.

[30]  L. Maier,et al.  Modulation of Cardiac Na+ and Ca2+ Currents by CaM and CaMKII , 2006, Journal of cardiovascular electrophysiology.

[31]  Da-Zhi Wang,et al.  Myocardin Induces Cardiomyocyte Hypertrophy , 2006, Circulation research.

[32]  K. Sunagawa,et al.  Overexpression of Mitochondrial Peroxiredoxin-3 Prevents Left Ventricular Remodeling and Failure After Myocardial Infarction in Mice , 2006, Circulation.

[33]  A. Shah,et al.  NADPH oxidase and heart failure. , 2006, Current opinion in pharmacology.

[34]  Mark A Sussman,et al.  The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits , 2006, Circulation research.

[35]  B. Su,et al.  Protein Kinase-mediated Regulation of Calcineurin through the Phosphorylation of Modulatory Calcineurin-interacting Protein 1* , 2006, Journal of Biological Chemistry.

[36]  Wei Zhang,et al.  Selective Loss of Fine Tuning of Gq/11 Signaling by RGS2 Protein Exacerbates Cardiomyocyte Hypertrophy* , 2006, Journal of Biological Chemistry.

[37]  K. Tomizawa,et al.  A Cell‐permeable NFAT Inhibitor Peptide Prevents Pressure‐Overload Cardiac Hypertrophy , 2006, Chemical biology & drug design.

[38]  C. Lugnier.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. , 2006, Pharmacology & therapeutics.

[39]  Tong Zhang,et al.  Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. , 2006, The Journal of clinical investigation.

[40]  T. Iwasaka,et al.  Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. , 2006, Cardiovascular research.

[41]  D. Clapham,et al.  An introduction to TRP channels. , 2006, Annual review of physiology.

[42]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[43]  Michael Kohlhaas,et al.  Increased Sarcoplasmic Reticulum Calcium Leak but Unaltered Contractility by Acute CaMKII Overexpression in Isolated Rabbit Cardiac Myocytes , 2006, Circulation research.

[44]  R. Saraiva,et al.  Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy , 2006, Circulation research.

[45]  M. Jeong,et al.  Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding , 2005, Circulation.

[46]  F. Hofmann,et al.  Function of cGMP-dependent protein kinases as revealed by gene deletion. , 2006, Physiological reviews.

[47]  H. Hidaka,et al.  Development of specific Rho-kinase inhibitors and their clinical application. , 2005, Biochimica et biophysica acta.

[48]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[49]  S. Houser,et al.  Nuclear Targeting of Akt Enhances Ventricular Function and Myocyte Contractility , 2005, Circulation research.

[50]  M. Anderson.  The fire from within: the biggest Ca2+ channel erupts and dribbles. , 2005, Circulation research.

[51]  D. Bers,et al.  Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.

[52]  Angus C. Nairn,et al.  Structure of the Autoinhibited Kinase Domain of CaMKII and SAXS Analysis of the Holoenzyme , 2005, Cell.

[53]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[54]  J. Molkentin,et al.  The DnaJ-Related Factor Mrj Interacts with Nuclear Factor of Activated T Cells c3 and Mediates Transcriptional Repression through Class II Histone Deacetylase Recruitment , 2005, Molecular and Cellular Biology.

[55]  P. Hogan,et al.  Inhibition of the Calcineurin-NFAT Interaction by Small Organic Molecules Reflects Binding at an Allosteric Site* , 2005, Journal of Biological Chemistry.

[56]  R. Colavitti,et al.  This Review Is Part of a Thematic Series on New Paradigms of Transcriptional Control of Myocardial and Vascular Growth, Which Includes the following Articles: Redox-dependent Transcriptional Regulation Excitation-transcription Coupling Redox-dependent Transcriptional Regulation Review Mammalian Redo , 2022 .

[57]  Chao-Yung Wang,et al.  Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1+/− Haploinsufficient Mice , 2005, Circulation.

[58]  W. Frishman,et al.  Rho-Kinase Inhibition in the Therapy of Cardiovascular Disease , 2005, Cardiology in review.

[59]  R. DePinho,et al.  Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy , 2005, Molecular and Cellular Biology.

[60]  P. Bueno,et al.  Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats. , 2005, American journal of physiology. Endocrinology and metabolism.

[61]  J. McGill,et al.  The effect of ruboxistaurin on nephropathy in type 2 diabetes. , 2005, Diabetes care.

[62]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[63]  M. Beckerle,et al.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. , 2005, The Journal of clinical investigation.

[64]  Irwin Klein,et al.  Effect of serum triiodothyronine on regulation of cardiac gene expression: role of histone acetylation. , 2005, American journal of physiology. Heart and circulatory physiology.

[65]  W. Leary,et al.  Allopurinol or Oxypurinol in Heart Failure Therapy – a Promising New Development or End of Story? , 2005, Cardiovascular Drugs and Therapy.

[66]  A. Zeiher,et al.  Glycogen Synthase Kinase 3 (cid:1) Inhibits Myocardin-Dependent Transcription and Hypertrophy Induction Through Site-Specific Phosphorylation , 2022 .

[67]  F. McKeon,et al.  Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  A. Takeshita,et al.  Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine , 2005 .

[69]  L. Amado,et al.  Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. , 2005, Journal of molecular and cellular cardiology.

[70]  J. Putney,et al.  Mechanism of Inhibition of TRPC Cation Channels by 2-Aminoethoxydiphenylborane , 2005, Molecular Pharmacology.

[71]  J. Downey,et al.  Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria , 2005, Circulation research.

[72]  Yuan Zhang,et al.  Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. , 2005, Journal of molecular and cellular cardiology.

[73]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[74]  D. Sane,et al.  Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report , 2005, Circulation.

[75]  Y. Hattori,et al.  Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress , 2005, Journal of hypertension.

[76]  P. Madeddu.  Correction of endothelial dysfunction by tetrahydrobiopterin: new hope for the treatment of arterial hypertension? , 2005, Journal of hypertension.

[77]  Donald M Bers,et al.  Calcium Signaling in Cardiac Ventricular Myocytes , 2005, Annals of the New York Academy of Sciences.

[78]  A. Goldberg,et al.  The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling* , 2005, Journal of Biological Chemistry.

[79]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[80]  D. Maurice.  Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. , 2005, Frontiers in bioscience : a journal and virtual library.

[81]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[82]  HelmutDrexler,et al.  Increased Collagen Deposition and Diastolic Dysfunction but Preserved Myocardial Hypertrophy After Pressure Overload in Mice Lacking PKCε , 2005 .

[83]  P. D. de Tombe,et al.  Functional Effects of Rho-Kinase–Dependent Phosphorylation of Specific Sites on Cardiac Troponin , 2005, Circulation research.

[84]  H. Drexler,et al.  Increased Collagen Deposition and Diastolic Dysfunction but Preserved Myocardial Hypertrophy After Pressure Overload in Mice Lacking PKC&egr; , 2005, Circulation research.

[85]  M. Halks-Miller,et al.  Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. , 2005, European journal of pharmacology.

[86]  E. Rozengurt,et al.  Protein Kinase D Signaling* , 2005, Journal of Biological Chemistry.

[87]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[88]  Guy Salama,et al.  Calmodulin kinase II inhibition protects against structural heart disease , 2005, Nature Medicine.

[89]  Rong Zeng,et al.  Regulation of PTEN by Rho small GTPases , 2005, Nature Cell Biology.

[90]  J. Soboloff,et al.  A Functional Link between Store-operated and TRPC Channels Revealed by the 3,5-Bis(trifluoromethyl)pyrazole Derivative, BTP2* , 2005, Journal of Biological Chemistry.

[91]  L. Karlsson,et al.  Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. , 2005, Journal of medicinal chemistry.

[92]  Hiroko Oshima,et al.  ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles , 2005, The Journal of cell biology.

[93]  H. Yamawaki,et al.  Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels , 2005, Current opinion in nephrology and hypertension.

[94]  Mahesh P. Gupta,et al.  Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. , 2005, American journal of physiology. Heart and circulatory physiology.

[95]  Frank J Giordano,et al.  Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.

[96]  E. Olson,et al.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. , 2005, The Journal of clinical investigation.

[97]  G. Dorn,et al.  Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.

[98]  S. Sankey,et al.  Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. , 2005, Journal of cardiac failure.

[99]  A. Kurosky,et al.  TRPC1 forms the stretch-activated cation channel in vertebrate cells , 2005, Nature Cell Biology.

[100]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[101]  De-Pei Liu,et al.  Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. , 2005, Free radical biology & medicine.

[102]  A. Ganesan,et al.  The Transcriptional Coactivator p300 Plays a Critical Role in the Hypertrophic and Protective Pathways Induced by Phenylephrine in Cardiac Cells but Is Specific to the Hypertrophic Effect of Urocortin , 2005, Chembiochem : a European journal of chemical biology.

[103]  Jun O. Liu,et al.  Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. , 2004, Journal of molecular biology.

[104]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[105]  Grupa badawcza Pkc-Drs.  The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy. Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial , 2005 .

[106]  U. Laufs,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[107]  A. Nishiyama,et al.  Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. , 2005, Cardiovascular research.

[108]  P. Aiello.  The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. , 2005, Diabetes.

[109]  B. Harrison,et al.  The CRM1 Nuclear Export Receptor Controls Pathological Cardiac Gene Expression , 2004, Molecular and Cellular Biology.

[110]  J. Putney,et al.  The mammalian TRPC cation channels. , 2004, Biochimica et biophysica acta.

[111]  J. Soboloff,et al.  Sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) gene silencing and remodeling of the Ca2+ signaling mechanism in cardiac myocytes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[112]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[113]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[114]  Michael S Lauer,et al.  Left ventricular hypertrophy: the next treatable, silent killer? , 2004, JAMA.

[115]  E. Olson,et al.  Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress , 2004, Nature Medicine.

[116]  S. Vatner,et al.  Silent Information Regulator 2&agr;, a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes , 2004, Circulation research.

[117]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[118]  H. Drexler,et al.  Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction: A New Action for an Old Drug? , 2004, Circulation.

[119]  J. Molkentin,et al.  Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. , 2004, Biochemical and biophysical research communications.

[120]  E. Olson,et al.  Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development , 2004, Molecular and Cellular Biology.

[121]  J. Liao,et al.  Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[122]  Rick B. Vega,et al.  Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5 , 2004, Molecular and Cellular Biology.

[123]  M. Nieminen,et al.  Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial , 2004, Circulation.

[124]  C. Proud.  Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. , 2004, Cardiovascular research.

[125]  Anthony J. Muslin,et al.  Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure Overload , 2004, Circulation.

[126]  A. Takeshita,et al.  Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. , 2004, Journal of molecular and cellular cardiology.

[127]  J. Liao,et al.  Statins and myocardial hypertrophy. , 2004, Coronary artery disease.

[128]  M. Crackower,et al.  The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. , 2004, Journal of molecular and cellular cardiology.

[129]  Anita Y. M. Chan,et al.  Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte* , 2004, Journal of Biological Chemistry.

[130]  M. Boluyt,et al.  The mTOR/p70S6K Signal Transduction Pathway Plays a Role in Cardiac Hypertrophy and Influences Expression of Myosin Heavy Chain Genes in vivo , 2004, Cardiovascular Drugs and Therapy.

[131]  R. Bassel-Duby,et al.  TRPC3 channels confer cellular memory of recent neuromuscular activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[132]  S. Izumo,et al.  Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.

[133]  B. DeDecker,et al.  Chemical genetics to identify NFAT inhibitors: Potential of targeting calcium mobilization in immunosuppression , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[134]  G. Wagner,et al.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[135]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Left Ventricular Remodeling After Myocardial Infarction in Mice , 2004, Circulation.

[136]  Statin Therapy for Cardiac Hypertrophy and Heart Failure , 2004, Journal of Investigative Medicine.

[137]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[138]  L. Sleeper,et al.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. , 2004, Journal of the American College of Cardiology.

[139]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[140]  M. Hoth,et al.  Potent Inhibition of Ca2+ Release-activated Ca2+ Channels and T-lymphocyte Activation by the Pyrazole Derivative BTP2* , 2004, Journal of Biological Chemistry.

[141]  J. Hare,et al.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.

[142]  Masahiro Ito,et al.  Pressure Overload–Induced Myocardial Hypertrophy in Mice Does Not Require gp91phox , 2004, Circulation.

[143]  E. Olson,et al.  A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[144]  T. Hewett,et al.  PKC-α regulates cardiac contractility and propensity toward heart failure , 2004, Nature Medicine.

[145]  J. Lambeth.  NOX enzymes and the biology of reactive oxygen , 2004, Nature Reviews Immunology.

[146]  N. Alp,et al.  Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[147]  P. Doevendans,et al.  MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction , 2004, Circulation research.

[148]  R. Clarke,et al.  Antioxidant Vitamins and Risk of Cardiovascular Disease. Review of Large-Scale Randomised Trials , 2002, Cardiovascular Drugs and Therapy.

[149]  P. Karczewski,et al.  Expression of Ca2+/calmodulin-dependent protein kinase II δ-subunit isoforms in rats with hypertensive cardiac hypertrophy , 2001, Molecular and Cellular Biochemistry.

[150]  Andre Levchenko,et al.  GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. , 2004, Genes & development.

[151]  M. Hoth,et al.  Potent Inhibition of Ca 2 Release-activated Ca 2 Channels and T-lymphocyte Activation by the Pyrazole Derivative BTP 2 * , 2004 .

[152]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.

[153]  P. Doevendans,et al.  MCIP 1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction , 2004 .

[154]  S. Miyamoto,et al.  Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes? , 2004, Recent progress in hormone research.

[155]  Pamela A. Silver,et al.  A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. , 2003, Cancer cell.

[156]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[157]  Anthony J. Muslin,et al.  Role of 14-3-3-Mediated p38 Mitogen-Activated Protein Kinase Inhibition in Cardiac Myocyte Survival , 2003, Circulation research.

[158]  G. Dorn,et al.  Protein Kinase C (cid:1) Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy , 2022 .

[159]  R. Pilz,et al.  This Review Is Part of a Thematic Series on Cyclic Gmp–generating Enzymes and Cyclic Gmp–dependent Signaling, Which Includes the following Articles: Regulation of Nitric Oxide–sensitive Guanylyl Cyclase Cyclic Gmp Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and , 2022 .

[160]  U. Walter,et al.  Increased effects of C‐type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP‐dependent protein kinase I , 2003, British journal of pharmacology.

[161]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[162]  L. Cantley,et al.  Rheb fills a GAP between TSC and TOR. , 2003, Trends in biochemical sciences.

[163]  Jing Liu,et al.  Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. , 2003, The Journal of clinical investigation.

[164]  A. Shah,et al.  Contrasting Roles of NADPH Oxidase Isoforms in Pressure-Overload Versus Angiotensin II–Induced Cardiac Hypertrophy , 2003, Circulation research.

[165]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System , 2003, Circulation research.

[166]  Dianqing Wu,et al.  Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. , 2003, The Journal of clinical investigation.

[167]  J. Epstein,et al.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. , 2003, The Journal of clinical investigation.

[168]  K. Rockett,et al.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. , 2003, The Journal of clinical investigation.

[169]  I. Komuro,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. , 2003, Journal of molecular and cellular cardiology.

[170]  E. Olson,et al.  Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors* , 2003, Journal of Biological Chemistry.

[171]  S. Narumiya,et al.  Targeted Disruption of the Mouse Rho-Associated Kinase 2 Gene Results in Intrauterine Growth Retardation and Fetal Death , 2003, Molecular and Cellular Biology.

[172]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[173]  J. Liao,et al.  NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. , 2003, Journal of molecular and cellular cardiology.

[174]  Jun Ren,et al.  Cardiac-specific overexpression of catalase rescues ventricular myocytes from ethanol-induced cardiac contractile defect. , 2003, Journal of molecular and cellular cardiology.

[175]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[176]  G. Makhlouf,et al.  Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[177]  H. Cingolani,et al.  Regression of Isoproterenol‐Induced Cardiac Hypertrophy by Na+/H+ Exchanger Inhibition , 2003, Hypertension.

[178]  Tong Zhang,et al.  Transgenic CaMKII&dgr;C Overexpression Uniquely Alters Cardiac Myocyte Ca2+ Handling: Reduced SR Ca2+ Load and Activated SR Ca2+ Release , 2003, Circulation research.

[179]  Tong Zhang,et al.  The &dgr;C Isoform of CaMKII Is Activated in Cardiac Hypertrophy and Induces Dilated Cardiomyopathy and Heart Failure , 2003, Circulation research.

[180]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[181]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[182]  Lin Chen,et al.  Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2 , 2003, Nature.

[183]  Michael D. Schneider,et al.  Telomere attrition and Chk2 activation in human heart failure , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[184]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[185]  G. D. Johnston,et al.  Functional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure , 2003, Circulation.

[186]  W. Manning,et al.  Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.

[187]  A. Shah,et al.  Oxidative stress and heart failure , 2003, Archives des maladies du coeur et des vaisseaux.

[188]  B. Kobilka,et al.  Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. , 2003, The Journal of clinical investigation.

[189]  E. Clementi,et al.  Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide , 2003, Science.

[190]  A. Means,et al.  Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo. , 2003, Molecular endocrinology.

[191]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.

[192]  D. Bers,et al.  Transgenic CaMKII C Overexpression Uniquely Alters Cardiac Myocyte Ca , 2003 .

[193]  E. Sausville.  Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. , 2003, Current medicinal chemistry. Anti-cancer agents.

[194]  Y. Yoshikawa,et al.  Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. , 2003, Journal of molecular and cellular cardiology.

[195]  J. Molkentin,et al.  Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth , 2002, Molecular and Cellular Biology.

[196]  A. Giordano,et al.  Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy , 2002, Nature Medicine.

[197]  G. Dorn,et al.  Ischemic Protection and Myofibrillar Cardiomyopathy: Dose-Dependent Effects of In Vivo &dgr;PKC Inhibition , 2002, Circulation research.

[198]  E. Olson,et al.  Association of Class II Histone Deacetylases with Heterochromatin Protein 1: Potential Role for Histone Methylation in Control of Muscle Differentiation , 2002, Molecular and Cellular Biology.

[199]  A. Shah,et al.  Activation of NADPH Oxidase During Progression of Cardiac Hypertrophy to Failure , 2002, Hypertension.

[200]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[201]  Dan M Roden,et al.  Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy , 2002, Circulation.

[202]  N. Kobayashi,et al.  Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. , 2002, Cardiovascular research.

[203]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[204]  P. Ghezzi,et al.  Glutathionylation of human thioredoxin: A possible crosstalk between the glutathione and thioredoxin systems , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[205]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[206]  J. Sadoshima,et al.  Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. , 2002, Circulation Research.

[207]  E. Olson,et al.  Calsarcin-3, a Novel Skeletal Muscle-specific Member of the Calsarcin Family, Interacts with Multiple Z-disc Proteins* , 2002, The Journal of Biological Chemistry.

[208]  G. Crabtree,et al.  NFAT Signaling Choreographing the Social Lives of Cells , 2002, Cell.

[209]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[210]  A. Shah,et al.  Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.

[211]  J. Molkentin,et al.  Impaired cardiac hypertrophic response in Calcineurin Aβ-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[212]  M. Hori,et al.  The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. , 2002, Journal of the American College of Cardiology.

[213]  D. Kass,et al.  Imbalance Between Xanthine Oxidase and Nitric Oxide Synthase Signaling Pathways Underlies Mechanoenergetic Uncoupling in the Failing Heart , 2002, Circulation research.

[214]  A. Shah,et al.  Pivotal Role of a gp91phox-Containing NADPH Oxidase in Angiotensin II-Induced Cardiac Hypertrophy in Mice , 2002, Circulation.

[215]  Tong Zhang,et al.  The Cardiac-specific Nuclear δB Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Induces Hypertrophy and Dilated Cardiomyopathy Associated with Increased Protein Phosphatase 2A Activity* , 2002, The Journal of Biological Chemistry.

[216]  E. Olson,et al.  Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[217]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[218]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[219]  Julie A. Wilkins,et al.  Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds* , 2001, The Journal of Biological Chemistry.

[220]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[221]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[222]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[223]  E. Olson,et al.  Identification of a Signal-Responsive Nuclear Export Sequence in Class II Histone Deacetylases , 2001, Molecular and Cellular Biology.

[224]  G. Dorn,et al.  Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and ɛPKC , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[225]  John C. Lee,et al.  Hypertensive End-Organ Damage and Premature Mortality Are p38 Mitogen-Activated Protein Kinase–Dependent in a Rat Model of Cardiac Hypertrophy and Dysfunction , 2001, Circulation.

[226]  W. Schmitz,et al.  Enhanced protein phosphorylation in hypertensive hypertrophy. , 2001, Cardiovascular research.

[227]  N. Tamura,et al.  Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. , 2001, Canadian journal of physiology and pharmacology.

[228]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[229]  F. Luft,et al.  Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor , 2001, Circulation.

[230]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[231]  S. Kudoh,et al.  Calcineurin Plays a Critical Role in the Development of Pressure Overload–Induced Cardiac Hypertrophy , 2001, Circulation.

[232]  T. Takenawa,et al.  Identification and Characterization of a Sac Domain-containing Phosphoinositide 5-Phosphatase* , 2001, The Journal of Biological Chemistry.

[233]  B. Staels,et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.

[234]  P. Buttrick,et al.  PKC-β is not necessary for cardiac hypertrophy , 2001 .

[235]  C. Roberts,et al.  Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. , 2001, Cellular signalling.

[236]  Rick B. Vega,et al.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[237]  R. Hajjar,et al.  Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[238]  E. Olson,et al.  Association of COOH-terminal-binding Protein (CtBP) and MEF2-interacting Transcription Repressor (MITR) Contributes to Transcriptional Repression of the MEF2 Transcription Factor* , 2001, The Journal of Biological Chemistry.

[239]  D. Sawyer,et al.  Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. , 2001, Journal of molecular and cellular cardiology.

[240]  E. Olson,et al.  Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[241]  E. Olson,et al.  Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[242]  James O. Mudd,et al.  An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .

[243]  E. Braunwald,et al.  Congestive Heart Failure: Fifty Years of Progress , 2000, Circulation.

[244]  S. Ogawa,et al.  Calmodulin Kinases II and IV and Calcineurin Are Involved in Leukemia Inhibitory Factor–Induced Cardiac Hypertrophy in Rats , 2000, Circulation research.

[245]  E. Olson,et al.  Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.

[246]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[247]  G. Dorn,et al.  ε Protein Kinase C in Pathological Myocardial Hypertrophy , 2000, The Journal of Biological Chemistry.

[248]  Barry I. Posner,et al.  Regulation of Histone Deacetylase 4 by Binding of 14-3-3 Proteins , 2000, Molecular and Cellular Biology.

[249]  Hiroyuki Tsutsui,et al.  Treatment With Dimethylthiourea Prevents Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction in Mice: Role of Oxidative Stress , 2000, Circulation research.

[250]  Xiaoping Zhou,et al.  3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. , 2000, Journal of medicinal chemistry.

[251]  C. Grozinger,et al.  Calcium Regulates Transcriptional Repression of Myocyte Enhancer Factor 2 by Histone Deacetylase 4* , 2000, The Journal of Biological Chemistry.

[252]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle* , 2000, The Journal of Biological Chemistry.

[253]  S. Schreiber,et al.  Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[254]  Qingbo Xu,et al.  Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. , 2000, Circulation.

[255]  G. Dorn,et al.  Cardiotrophic Effects of Protein Kinase C ε Analysis by In Vivo Modulation of PKCε Translocation , 2000 .

[256]  Y. Zou,et al.  Ca2+/Calmodulin-dependent Kinase II and Calcineurin Play Critical Roles in Endothelin-1-induced Cardiomyocyte Hypertrophy* , 2000, The Journal of Biological Chemistry.

[257]  R. Passier,et al.  CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. , 2000, The Journal of clinical investigation.

[258]  R. Roeder,et al.  HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.

[259]  Mark E. Anderson,et al.  Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels , 2000, Nature Cell Biology.

[260]  A. Takeshita,et al.  Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. , 2000, Circulation research.

[261]  A. Altman,et al.  Inhibition of the c-Jun N-terminal Kinase/AP-1 and NF-κB Pathways by PICOT, a Novel Protein Kinase C-interacting Protein with a Thioredoxin Homology Domain* , 2000, The Journal of Biological Chemistry.

[262]  A. Somlyo,et al.  Signal transduction by G‐proteins, Rho‐kinase and protein phosphatase to smooth muscle and non‐muscle myosin II , 2000, The Journal of physiology.

[263]  G. Dorn,et al.  Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq. , 2000, The Journal of biological chemistry.

[264]  C. Klee,et al.  Calcineurin: from structure to function. , 2000, Current topics in cellular regulation.

[265]  D. Barber,et al.  Effect of Rho GTPases on Na-H exchanger in mammalian cells. , 2000, Methods in enzymology.

[266]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[267]  A. Means,et al.  Regulatory cascades involving calmodulin-dependent protein kinases. , 2000, Molecular endocrinology.

[268]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[269]  Godfrey L. Smith,et al.  Calcium/calmodulin‐dependent protein kinase II activity is increased in sarcoplasmic reticulum from coronary artery ligated rabbit hearts , 1999, FEBS letters.

[270]  C. Roberts,et al.  Extracellular Signal-regulated Protein Kinase Activation Is Required for the Anti-hypertrophic Effect of Atrial Natriuretic Factor in Neonatal Rat Ventricular Myocytes* , 1999, The Journal of Biological Chemistry.

[271]  J. Balligand.  Regulation of cardiac beta-adrenergic response by nitric oxide. , 1999, Cardiovascular research.

[272]  D. Sawyer,et al.  Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. , 1999, Circulation research.

[273]  J. Shapiro,et al.  Intracellular Reactive Oxygen Species Mediate the Linkage of Na+/K+-ATPase to Hypertrophy and Its Marker Genes in Cardiac Myocytes* , 1999, The Journal of Biological Chemistry.

[274]  W. Schmitz,et al.  Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. , 1999, Cardiovascular research.

[275]  G. King,et al.  Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. , 1999, Circulation.

[276]  R. Ritchie,et al.  Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. , 1998, American journal of physiology. Heart and circulatory physiology.

[277]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[278]  K. Mihara,et al.  Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. , 1998, Circulation.

[279]  D. Barber,et al.  Na-H exchange acts downstream of RhoA to regulate integrin-induced cell adhesion and spreading. , 1998, Molecular biology of the cell.

[280]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[281]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[282]  N. Takahashi,et al.  Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. , 1998, The Journal of clinical investigation.

[283]  H. Schulman,et al.  The Nuclear δB Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Regulates Atrial Natriuretic Factor Gene Expression in Ventricular Myocytes* , 1997, The Journal of Biological Chemistry.

[284]  T. Rabelink,et al.  Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. , 1997, Biochemical and biophysical research communications.

[285]  E. Lakatta,et al.  Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. , 1997, Circulation research.

[286]  H. Schmidt,et al.  No .NO from NO synthase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[287]  M. Gschwendt,et al.  Inhibition of protein kinase C μ by various inhibitors. Inhibition from protein kinase c isoenzymes , 1996 .

[288]  K. Nakao,et al.  ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.

[289]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[290]  M. Gschwendt,et al.  Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. , 1996, FEBS letters.

[291]  J. Sadoshima,et al.  Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. , 1995, Circulation research.

[292]  M. Hori,et al.  Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction. , 1994, The American journal of physiology.

[293]  Andrew P. Somlyo,et al.  Signal transduction and regulation in smooth muscle , 1994, Nature.

[294]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[295]  D. Stuehr,et al.  Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[296]  H. Schulman,et al.  The multifunctional Ca2+/calmodulin-dependent protein kinases. , 1993, Current opinion in cell biology.

[297]  S. Nakanishi,et al.  Potent and preferential inhibition of Ca2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926. , 1991, Biochemical and biophysical research communications.

[298]  H. Schulman,et al.  Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. , 1991, The Journal of biological chemistry.

[299]  D. Goeddel,et al.  Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). , 1991, Science.

[300]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[301]  H Fujisawa,et al.  Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. , 1989, The Journal of biological chemistry.

[302]  J. H. Collins,et al.  Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. , 1986, The Journal of biological chemistry.

[303]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.